About Xyphos Biosciences

About company

Xyphos Biosciences develops a CAR-T cell therapy platform called ACCEL (Advanced Cellular Control through Engineered Ligands), for treating relapsed hematological malignancies and solid tumors. The platform enables precise control of activity and targeting of universal CAR-T cell, termed convertibleCAR-T, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells.